Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$16.57 USD
-0.03 (-0.18%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.57 USD
-0.03 (-0.18%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Zacks News
KemPharm Posts Positive Top-Line Results on KP415 Prodrug
by Zacks Equity Research
KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.
Endocyte (ECYT) Soars: Stock Adds 11.4% in Session
by Zacks Equity Research
Endocyte (ECYT) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Biogen Begins Phase III Study on Ischemic Stroke Candidate
by Zacks Equity Research
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is looking like an interesting pick from a technical perspective
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 166.67% and 5.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.
Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?
by Zacks Equity Research
On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.
Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.
Aerie (AERI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.
What's in Store for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.
Is a Beat in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.
Pacira Focused on Exparel Development Amid Competition
by Zacks Equity Research
Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
by Zacks Equity Research
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Okays Label Expansion of Pacira's Exparel's, Stock Up
by Zacks Equity Research
Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.
Company News For Apr 9, 2018
by Zacks Equity Research
Companies in the news are: PSMT,CPB,BWEN,PCRX